Algert Global LLC Has $2.38 Million Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Algert Global LLC lessened its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 33.3% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 82,411 shares of the company’s stock after selling 41,217 shares during the quarter. Algert Global LLC’s holdings in Apellis Pharmaceuticals were worth $2,377,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. increased its stake in shares of Apellis Pharmaceuticals by 1,300.8% in the first quarter. Russell Investments Group Ltd. now owns 3,586 shares of the company’s stock worth $211,000 after acquiring an additional 3,330 shares during the last quarter. CANADA LIFE ASSURANCE Co increased its position in Apellis Pharmaceuticals by 107.7% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 16,677 shares of the company’s stock worth $981,000 after purchasing an additional 8,647 shares during the last quarter. Jacobs Levy Equity Management Inc. raised its stake in shares of Apellis Pharmaceuticals by 4.7% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 20,057 shares of the company’s stock worth $1,179,000 after purchasing an additional 903 shares in the last quarter. Tidal Investments LLC acquired a new stake in shares of Apellis Pharmaceuticals during the 1st quarter valued at about $266,000. Finally, Comerica Bank grew its stake in shares of Apellis Pharmaceuticals by 500.7% in the 1st quarter. Comerica Bank now owns 8,163 shares of the company’s stock valued at $480,000 after buying an additional 6,804 shares in the last quarter. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Stock Up 2.3 %

Shares of APLS opened at $32.63 on Wednesday. Apellis Pharmaceuticals, Inc. has a 52 week low of $24.34 and a 52 week high of $73.80. The firm has a market capitalization of $4.06 billion, a P/E ratio of -16.07 and a beta of 0.87. The company has a 50-day simple moving average of $28.83 and a 200-day simple moving average of $35.48. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). The firm had revenue of $196.83 million during the quarter, compared to the consensus estimate of $200.00 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. Apellis Pharmaceuticals’s revenue was up 78.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.17) EPS. On average, equities research analysts expect that Apellis Pharmaceuticals, Inc. will post -1.71 earnings per share for the current year.

Wall Street Analyst Weigh In

APLS has been the subject of a number of analyst reports. Scotiabank reduced their target price on shares of Apellis Pharmaceuticals from $35.00 to $30.00 and set a “sector perform” rating for the company in a research note on Wednesday, November 6th. William Blair started coverage on shares of Apellis Pharmaceuticals in a report on Wednesday, October 16th. They issued an “outperform” rating for the company. Robert W. Baird lowered their target price on shares of Apellis Pharmaceuticals from $92.00 to $55.00 and set an “outperform” rating on the stock in a research report on Thursday, November 7th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $80.00 price target on shares of Apellis Pharmaceuticals in a research report on Wednesday, July 31st. Finally, Bank of America lowered their price objective on Apellis Pharmaceuticals from $61.00 to $47.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Seven investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $49.94.

Insider Buying and Selling at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, Director A. Sinclair Dunlop sold 37,000 shares of the firm’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $36.23, for a total transaction of $1,340,510.00. Following the completion of the transaction, the director now owns 100,000 shares in the company, valued at $3,623,000. This trade represents a 27.01 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 6.80% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).